Cell therapy is one of the most promising advances in modern cancer treatment. The basic concept involves collecting a patient’s own immune cells, genetically reprogramming them in the laboratory so they recognize cancer more effectively, and then infusing them back into the patient’s body. Once circulating, these enhanced immune cells are designed to seek out and destroy cancer cells while leaving healthy tissue largely untouched. The approach has already produced remarkable results in certain blood cancers, where engineered CAR T-cell therapies have driven durable remissions in patients who had exhausted conventional options. Translating that success to solid tumors, however, has proven far more difficult. Solid tumors build defensive microenvironments that suppress immune activity, physically exclude T cells and exhaust the cells that do manage to infiltrate. The new UChicago Medicine trial is designed specifically to confront those barriers, combining tumor recognition with engineered resistance to the immunosuppressive signals that tumors deploy.

The scientific foundation of the treatment differs in an important way from existing CAR T-cell platforms. Conventional CAR T cells use engineered synthetic receptors that recognize proteins displayed on the surface of cancer cells. The UChicago team, by contrast, is using specially engineered T-cell receptors, the natural antigen-recognition machinery of the immune system, which allow immune cells to detect protein fragments presented from inside cancer cells. This distinction matters enormously for the range of cancers that can be targeted. Many of the most attractive tumor-associated proteins are not displayed on the cell surface but are processed internally and presented on major histocompatibility complex molecules, invisible to CAR constructs but perfectly visible to a properly directed T-cell receptor. By exploiting this intracellular surveillance pathway, the researchers dramatically expand the universe of tumors that engineered cell therapies might plausibly attack.

Richard Koya, MD, PhD, Professor of Obstetrics and Gynecology at UChicago Medicine, is the scientific investigator who developed the treatment and designed the clinical trial on the basis of many years of laboratory research. He framed the strategy as an extension of the immune system’s own logic. The team, he explained, is using the same natural process the immune system relies on to fight infections, but redirecting it to attack cancer. The stated goal is to create immune cells that can recognize cancer more effectively, survive longer and continue fighting the disease over time. That emphasis on persistence reflects a central lesson of immunotherapy research: engineered cells that fade quickly or become dysfunctional inside tumors rarely produce lasting benefit, whereas cells that endure and form immune memory may hold tumors in check long after the initial infusion.

The treatment protocol unfolds in several carefully sequenced stages. Doctors will first collect a patient’s white blood cells through a process similar to blood donation. Patients will then receive the chemotherapy drug decitabine, chosen for a specific biological effect: it increases the production of a cancer protein called NY-ESO-1, a target found in many tumors but absent from healthy adult tissues. This priming step is intended to make tumor cells more visible to the engineered immune cells that will follow. In the laboratory, researchers will then genetically engineer the patient’s immune cells with two critical features. The first is a T-cell receptor that recognizes NY-ESO-1, equipping the cells to identify and attack cancer. The second is a genetic modification that blocks TGF-beta, a signaling molecule that normally suppresses immune responses and contributes to T-cell exhaustion inside tumors, one of the principal reasons cell therapies have underperformed against solid disease.

Once the engineering is complete, the enhanced immune cells will be infused back into the patient through an intravenous line, much like a blood transfusion. Patients will also receive a low dose of interleukin-2, an immune-boosting drug that helps the engineered T cells multiply and remain active after they enter the body. The investigators plan to infuse approximately one billion engineered T cells into each patient, a dose intended to generate a powerful and durable immune response against cancers that currently have few effective treatment options. Researchers believe this combination, antigen targeting, resistance to suppressive signaling and cytokine support, could produce a stronger and longer-lasting immune response because it addresses one of the biggest challenges in solid tumor treatment: the hostile tumor environment that often weakens cancer-fighting immune cells before they can eliminate the tumor. By engineering T cells to resist signals such as TGF-beta, the team hopes the cells will persist longer, develop lasting immune memory and continue attacking tumors over time.

The trial’s design and execution are notable for their institutional provenance. This is an investigator-initiated clinical trial, meaning the treatment was conceived and developed by University of Chicago researchers rather than a commercial sponsor. The UChicago Medicine Comprehensive Cancer Center, which operates one of the nation’s largest cancer clinical trials programs, has extensive experience translating laboratory discoveries into early-stage clinical studies, and that infrastructure is now being applied to a therapy the institution controls end to end. Critically, the engineered cells will be produced in UChicago Medicine’s Good Manufacturing Practices facility, a highly specialized laboratory that meets strict federal standards for producing cell therapies. On-site manufacturing allows researchers to oversee every step of the process, maintain quality control and accelerate the translation of discoveries from the laboratory to patients, a capability that very few academic medical centers possess.

Koya emphasized the strategic value of that capability. Very few academic medical centers, he noted, have the ability to manufacture personalized cell therapies entirely on-site, and he described the arrangement as giving the team tremendous flexibility to rapidly test new ideas and move promising treatments to patients. That flexibility is particularly consequential in the fast-moving field of cellular immunotherapy, where iterative design changes, new receptor constructs and combination strategies often emerge faster than commercial pipelines can accommodate. An academic GMP facility effectively shortens the distance between a laboratory observation and a patient-ready product, allowing investigators to refine the therapy across successive cohorts in ways that industry-sponsored trials, bound by fixed manufacturing contracts and regulatory timelines, often cannot.

The Phase 1/2A trial will evaluate the experimental therapy in a small group of patients with metastatic ovarian cancer, soft tissue sarcoma, bladder cancer, prostate cancer, breast cancer, melanoma or non-small cell lung cancer, all cancers that form solid tumors and all diseases in which effective options narrow sharply once the disease has spread. Beginning in October 2026, screening for eligible patients will take place at UChicago Medicine locations in Hyde Park, New Lenox, Harvey, Flossmoor, Calumet City and Tinley Park in Illinois, and Crown Point in Indiana, with treatment taking place at the main campus in Hyde Park. UChicago Medicine oncologist Daniel Olson, MD, Assistant Professor of Medicine, is the clinical investigator overseeing the trial, while Thinle Chodon, MD, PhD, research professor, is overseeing production of the engineered cells in the institution’s GMP facility. The division of roles between clinical leadership and manufacturing oversight reflects the operational complexity of personalized cell therapy, in which each patient’s product is a bespoke biological medicine.

The launch arrives as UChicago Medicine continues to expand its cancer care and research enterprise. The institution was among the first medical centers in the country to offer FDA-approved CAR T-cell therapy for adults and children with certain blood cancers, and more recently became one of the first centers to provide tumor-infiltrating lymphocyte therapy for advanced melanoma, establishing a track record at the leading edge of cellular immunology. In April 2027, UChicago Medicine will open the AbbVie Foundation Cancer Pavilion, Chicago’s first freestanding cancer pavilion, intended to bring advanced diagnostics, innovative treatments, translational discoveries and comprehensive support services to patients and the surrounding community. For patients with advanced solid tumors, the new trial offers something more immediate: a chance to access an immunotherapy approach that targets hidden tumor proteins, resists the suppressive forces of the tumor microenvironment and is produced by the same institution treating them, a model of academic self-reliance that may shape how the next generation of cancer cell therapies reaches the clinic.

Subject of Research: A Phase 1/2A clinical trial of an investigator-developed engineered T-cell receptor therapy targeting NY-ESO-1 for advanced solid tumors

Article Title: UChicago Medicine launches homegrown cell therapy for advanced solid tumors

Article References: UChicago Medicine launches homegrown cell therapy for advanced solid tumors. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: cell therapy, T-cell receptor, solid tumors, NY-ESO-1, TGF-beta, ovarian cancer, CAR T-cell therapy, GMP manufacturing, clinical trial, immunotherapy, decitabine, interleukin-2

The work, published in iScience, addresses one of the most stubborn bottlenecks in the field. Although MSC-derived EVs have shown remarkable regenerative and immunomodulatory effects in preclinical models — including the modulation of ischemic injury after myocardial infarction — clinical translation has been hampered by the absence of standardized, scalable, and regulatory-compliant manufacturing processes. There is no consensus on a single optimal isolation method, and existing techniques involve trade-offs between purity, yield, and preservation of functional activity. The new study tackles this problem head-on by building an integrated, semi-automated workflow that spans the entire production chain, from cell expansion to final product storage.

The platform begins with clinical-grade Wharton’s jelly-derived MSCs from a validated Master Cell Bank, expanded in a single-use 0.5-liter stirred-tank bioreactor on GMP-grade polystyrene microcarriers, using a chemically defined, serum-free medium. This upstream design is significant for two reasons. First, the microcarrier-based bioreactor configuration supports future scale-out, a critical requirement for commercial production. Second, the chemically defined medium eliminates animal-derived components such as fetal bovine serum or human platelet lysate, which dramatically reduces the risk of contamination by exogenous vesicles or adventitious agents and improves batch-to-batch reproducibility — both essential for therapeutic use.

Over seven days of culture, the cells grew from an initial seeding of 1.8 × 10⁷ to an average of 7.1 × 10⁷ cells, an expansion factor of roughly 2.8. Cell viability remained consistently above 70 percent across all batches, and phenotypic analysis confirmed stable expression of MSC markers (CD90, CD105, CD73) with no detectable hematopoietic or endothelial contaminants. One recurring operational challenge was the formation of cell–microcarrier aggregates, which complicated cell enumeration; the researchers compensated by monitoring lactate levels as a surrogate for metabolic activity, and they note that future optimization of detachment conditions and hydrodynamic parameters could further reduce this counting bias.

The conditioned medium harvested from the bioreactor — designated Intermediate Product 1 — was then concentrated using tangential flow filtration (TFF), a technique in which fluid flows parallel to a semi-permeable membrane rather than perpendicular to it. This crossflow design reduces membrane fouling and allows efficient retention of EVs while smaller molecules pass through. The team used a 750-kDa hollow-fiber cartridge, a higher cut-off than many comparable studies, which helps minimize soluble-protein retention and improves downstream purity. Each batch was processed in two consecutive TFF runs with an intermediate cleaning-in-place step, achieving a volumetric concentration factor of about 31 and a protein concentration factor of about 16, with remarkably low variability between batches.

Following concentration, the material was purified by automated size-exclusion chromatography (SEC) on an ÄKTA go system equipped with two HiLoad Superdex 200 columns. SEC separates particles based on size: larger vesicles elute first because they travel the shortest path through the porous matrix, while smaller contaminating proteins are retained longer. The system’s in-line sensors — monitoring UV absorbance, conductivity, pH, and pressure — enabled real-time process control, and a predefined UV threshold of 10 mAU automatically triggered collection of the EV-enriched fraction. This level of automation minimized operator presence in the cleanroom and reduced operator-introduced variability, a notable advance over previous GMP-aligned processes that relied on manual fraction collection.

The final product was then subjected to a rigorous panel of critical quality attributes (CQAs) aligned with both GMP standards and the Minimal Information for Studies of Extracellular Vesicles (MISEV) recommendations. Bead-based flow cytometry confirmed expression of EV-associated tetraspanins (CD9, CD63, CD81) and MSC markers (CD90, CD105, HLA-ABC), while non-specific markers remained undetectable. Nanoparticle tracking analysis revealed a mean particle concentration of 2.01 × 10¹⁰ particles per milliliter and a median size of 146.2 nanometers. Cryogenic transmission electron microscopy confirmed intact, bilayer-enclosed vesicles with minimal non-vesicular background. Protein and lipid concentrations, along with their ratios to particle number, remained stable across all four manufacturing batches.

Crucially, the researchers also demonstrated functional potency. CD73 enzymatic activity — which catalyzes the conversion of the proinflammatory molecule AMP into anti-inflammatory adenosine — was robustly detected and abolished by a specific inhibitor, confirming that the vesicles carry a defined immunomodulatory mechanism. In parallel, the EVs inhibited the proliferation of stimulated T cells from healthy donors by an average of about 18 percent, though without a consistent dose-response pattern. The authors are careful to note that these two assays interrogate distinct aspects of EV bioactivity and should not be expected to correlate directly; they propose CD73 activity as a promising candidate for routine batch release, while positioning the T cell assay as a complementary, higher-order biological readout.

Stability testing over 12 months of storage at −80°C in PlasmaLyte 148 — an excipient-free, parenteral-grade electrolyte solution — showed that protein concentrations, particle size, particle concentration, and CD73 activity were largely preserved. The authors emphasize that this one-year window represents the maximum duration experimentally validated to date, not a definitive expiry date, and that dedicated post-thaw in-use stability studies will be required before clinical administration. For now, they have adopted a conservative maximum post-thaw holding time of two hours.

The platform’s design is deliberately transposable. The three core unit operations — bioreactor-based cell expansion, tangential flow filtration, and size-exclusion chromatography — are individually well-established in regulated biomanufacturing environments, which may facilitate regulatory acceptance. Switching to a different MSC source or cell line would require re-tuning of upstream and downstream critical process parameters and re-definition of quality attributes, but the overall architecture can be retained. The authors acknowledge that their evaluation was limited to four manufacturing batches from two donors, and that formal cleaning validation under worst-case conditions remains necessary. Nevertheless, the demonstrated process control, product consistency, and frozen stability provide a robust foundation for advancing MSC-EV-based therapeutics from the laboratory bench toward the clinic — a milestone that could reshape how regenerative medicines are manufactured and delivered in the years ahead.

Subject of Research: GMP-compliant manufacturing and validation of extracellular vesicles from mesenchymal stromal cells

Article Title: Design and validation of a GMP-compliant manufacturing platform of extracellular vesicles from mesenchymal stromal cells

Article References: Courageux, Y., Monguió-Tortajada, M., López-Fernández, A., Schoch, L., Poblador, F., Morini, S., Prat-Vidal, C., Rodriguez, L., Torrents, S., Aran, G., Codinach, M., Gálvez-Montón, C., Bayes-Genis, A., Vives, J., Querol, S., & Roura, S. (2026). Design and validation of a GMP-compliant manufacturing platform of extracellular vesicles from mesenchymal stromal cells. iScience, 29(11), Article 117881. https://doi.org/10.1016/j.isci.2026.117881

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117881

Keywords: extracellular vesicles, mesenchymal stromal cells, GMP manufacturing, Wharton's jelly, tangential flow filtration, size-exclusion chromatography, regenerative medicine, advanced therapy medicinal products, immunomodulation, CD73, bioreactor, clinical translation

The research, led by Alessandra Colombini and Laura de Girolamo of the Orthopaedic Biotechnology Lab at IRCCS Galeazzi-Sant’Ambrogio Hospital in Milan, together with colleagues in Bari, Palermo, Turin, and Switzerland, set out to build a manufacturing framework that satisfies Good Manufacturing Practice, or GMP, the regulatory standard required for any cell therapy destined for patients. The team focused on chondrocytes, the specialized cells that produce and maintain cartilage matrix, and on a supplement called human platelet lysate, or hPL. Platelet lysate is produced from donated blood platelets that are ruptured to release their cargo of growth factors, and it has emerged as a leading candidate to replace fetal bovine serum, the traditional but problematic culture supplement that carries risks of immune reactions and pathogen transmission.

What distinguishes the new work is its insistence on treating cell expansion not as a laboratory art but as a controlled industrial process with defined critical quality attributes, abbreviated CQAs. In the language of pharmaceutical manufacturing, CQAs are the measurable properties a final product must possess to be safe and effective. For a chondrocyte therapy, those properties include the ability to proliferate robustly, a low immunogenic profile, retention of progenitor-associated surface markers, and, crucially, the capacity to deposit a proper cartilage-like extracellular matrix once the cells are returned to a three-dimensional environment. The Milan-led team designed their entire expansion protocol around preserving these attributes rather than simply maximizing cell numbers.

The experimental core of the study involved expanding human chondrocytes under low-density culture conditions in media supplemented with two different hPL formulations. Low-density seeding is a deliberate strategic choice. When cartilage cells are grown too densely, they tend to lose their specialized character and drift toward a fibroblast-like state, a phenomenon known as dedifferentiation that has plagued autologous chondrocyte implantation for decades. By keeping cells sparse, the researchers encouraged them to retain progenitor-like features. Their flow cytometry and marker analyses showed that the expanded populations expressed CD146 and CD166, surface molecules associated with chondrocyte progenitor cells, particularly under the low-density regime, while maintaining a low immunogenic profile that bodes well for autologous and potentially allogeneic applications.

To understand what the two platelet lysate formulations were actually delivering to the cells, the team turned to high-resolution mass spectrometry, profiling the protein composition of individual hPL batches and then applying bioinformatic analyses to identify differentially abundant proteins and enriched biological pathways. The results were striking: the two formulations differed significantly in their protein makeup, even though both supported efficient cell expansion. This finding carries an important manufacturing lesson. Two batches of hPL that perform similarly in a proliferation assay may nonetheless be biologically distinct, and a GMP-compliant process cannot afford to leave that variability uncharacterized. Proteomic batch characterization, the study suggests, belongs among the quality controls of any clinical-grade cell expansion protocol that relies on platelet lysate.

The decisive test of any expanded chondrocyte population is whether it can still make cartilage. The researchers addressed this by transferring the expanded cells into three-dimensional spheroid cultures, a format that mimics the condensed cell masses of early cartilage development. Histological and immunohistochemical analyses of the resulting spheroids revealed preserved chondrogenic capacity, with optimal extracellular matrix deposition observed at a seeding density of 200,000 cells per well. Both hPL conditions supported the production of type II collagen, the hallmark structural protein of hyaline cartilage, which is the tissue clinicians most want to regenerate. However, the two formulations produced measurable differences in glycosaminoglycan content, the charged sugar molecules that give cartilage its compressive resilience, and in type I collagen, a fibrous protein whose abundance can signal a shift toward less desirable, scar-like repair tissue.

On top of the biological optimization, the team implemented a formal risk-based manufacturing strategy using Failure Modes and Effects Analysis, or FMEA, a structured methodology borrowed from engineering and aerospace in which every step of a process is systematically scored for what could go wrong, how likely it is, and how severe the consequences would be. Applied to chondrocyte expansion, the FMEA identified the critical process parameters, or CPPs, that most strongly influence product quality, along with the associated risks at each stage. The analysis then pointed to targeted mitigation strategies, allowing the researchers to link each critical quality attribute to the process parameters that control it. This traceability, from risk to parameter to quality attribute, is precisely the architecture regulators expect when evaluating an advanced therapy medicinal product, or ATMP, for clinical trials.

The significance of the framework extends beyond cartilage. ATMPs, which include cell and gene therapies, are among the most heavily scrutinized products in medicine, and many promising candidates have stalled not because they failed in patients but because their manufacturing could not be made reproducible, scalable, and compliant. By demonstrating that biologically optimized culture conditions can be integrated with a structured risk assessment into a single GMP-compatible workflow, the Italian and Swiss consortium has provided a template that other cell therapy developers can adapt. The work was supported by the Italian Ministry of Health through its Ricerca Corrente funding program, and the study received ethics approval from the San Raffaele Hospital Ethics Committee, with written informed consent collected from all participants.

The authors are careful about where their findings sit on the translational timeline. The framework, they conclude, supports further preclinical validation and contributes to the development of scalable, clinically applicable therapies for cartilage repair, with a particular eye toward patients with early osteoarthritis, a population in which cell-based intervention has the best chance of altering disease course before joint damage becomes irreversible. Preclinical validation will need to confirm that the expanded, progenitor-enriched cells perform reliably in appropriate models, and eventual clinical studies will test whether the carefully preserved chondrogenic phenotype translates into durable cartilage repair in the joint. Still, the study resolves one of the field’s most persistent bottlenecks: it shows that human platelet lysate can support clinically compliant chondrocyte expansion without sacrificing the biological qualities that make the therapy worth manufacturing in the first place.

For the millions of people whose knees and other joints are slowly eroded by osteoarthritis, the study is a reminder that regenerative medicine advances as much through unglamorous process engineering as through biological discovery. The growth factors flooding a culture dish, the density at which cells are seeded, the batch-to-batch protein signature of a blood-derived supplement, and the failure modes of every handling step together determine whether a cartilage cell therapy reaches the operating room or dies in development. By mapping that entire landscape with proteomics, spheroid assays, and formal risk analysis, the researchers have turned a fragile laboratory procedure into something resembling a manufacturable medicine, and in doing so they have moved cartilage repair a tangible step closer to routine clinical practice.

Subject of Research: GMP-compliant expansion of human chondrocytes supplemented with human platelet lysate for cartilage repair

Article Title: Risk-based framework for GMP-compatible low-density platelet lysate-supplemented expansion of human cartilage cells for tissue repair

Article References: Colombini, A., Lopa, S., Raffo, V., Lo Pinto, M., Scilabra, S. D., Ferrero, I., Castiglia, S., Mareschi, K., Mangiavini, L., Moretti, M., & de Girolamo, L. (2026). Risk-based framework for GMP-compatible low-density platelet lysate-supplemented expansion of human cartilage cells for tissue repair. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08827-2

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08827-2

Keywords: chondrocytes, cartilage repair, human platelet lysate, GMP manufacturing, advanced therapy medicinal products, risk-based framework, FMEA, critical quality attributes, osteoarthritis, regenerative medicine, proteomics, cell therapy

Bacteriophages, the viruses that infect and kill bacteria, were first explored as therapeutic agents in the early twentieth century, shortly after their discovery by Frederick Twort and Félix d’Hérelle. While Western medicine largely abandoned the approach after the arrival of antibiotics, parts of Eastern Europe and the former Soviet Union never stopped using it. The new review, authored by a large consortium of researchers led by Roman Pantůček and Jiří Doškař of Masaryk University in Brno, documents how the Czech lands participated in this long tradition and how that historical foundation has been systematically rebuilt and modernized since the year 2000.

The review’s authors describe a national ecosystem in which academic institutions, biotechnology companies, and university hospitals work in parallel rather than in isolation. According to their analysis, more than 30 competitively funded research projects have been launched in the Czech Republic since 2000, addressing the central technical challenges that stand between laboratory phage research and routine clinical use. These projects have tackled phage safety assessment, genomic characterization of therapeutic candidates, formulation and delivery strategies, synergy between phages and conventional antibiotics, and the difficult problem of manufacturing phage preparations under Good Manufacturing Practice, the regulatory quality standard required for medicines.

The technical depth of this national effort is considerable. Genomic characterization, for example, is now understood as a non-negotiable prerequisite for any phage intended for human use, since phage genomes can harbor toxin genes or other undesirable cargo, and whole-genome sequencing allows candidate viruses to be screened before they ever reach a patient. The Czech teams have applied these methods extensively to staphylococcal phages, an area in which Masaryk University researchers have long specialized, reflecting the country’s historical focus on Staphylococcus aureus infections and conditions such as osteomyelitis, a stubborn bone infection that is notoriously difficult to treat with antibiotics alone and where topical phage preparations such as the long-standing Czech product Stafal found early application.

Stafal itself occupies an important place in the review’s historical narrative. Developed and produced in Czechoslovakia for decades, the staphylococcal phage preparation was used in the treatment of bacterial infections and became one of the few phage products in Europe with continuous production and clinical availability across the political upheavals of the twentieth century. Its survival into the modern era gave Czech researchers and clinicians a continuity of practical experience that few other Western or Central European countries can claim, and it served as a bridge between the empirical phage medicine of the past and today’s evidence-based, molecularly characterized approaches.

Clinical translation is now advancing along two complementary tracks. The first is treatment on a named-patient basis, a compassionate framework that allows physicians to administer phage preparations to individual patients with severe, otherwise untreatable infections, often under national regulations that accommodate unlicensed medicines when no authorized alternative exists. The second track consists of formal clinical trials, which the review describes as ongoing. Moving from anecdotal case reports to controlled studies is widely regarded by the phage therapy community as the decisive step toward regulatory acceptance, and the Czech combination of clinical partners and domestic GMP-compliant production places the country in a strong position to generate the kind of standardized evidence that regulators require.

The review also emphasizes that the Czech phage effort extends well beyond human medicine. In veterinary practice, phages have been investigated as alternatives to antibiotics in livestock, where reducing antimicrobial use has become a priority both for controlling resistance and for meeting European policy targets. In agriculture, researchers have explored phage-based biocontrol of plant pathogenic bacteria, an application studied at the Czech Academy of Sciences’ plant virology institute in České Budějovice. Food safety represents a third area of application, with phages offering a way to reduce pathogenic bacteria on food products without chemical residues. Together these sectors demonstrate a breadth of phage expertise that reinforces the human medicine pipeline, since methods for phage isolation, characterization, and formulation are largely transferable across applications.

Structural biology has added a distinctive dimension to the national program. At the Central European Institute of Technology in Brno, researchers including Pavel Plevka and Tibor Füzik apply cryo-electron microscopy to determine the atomic structures of phage particles, revealing how these viruses recognize their bacterial hosts and deliver their genetic material. Such structural insight is increasingly relevant to rational phage engineering, in which viruses are modified to broaden their host range, evade bacterial defense systems, or improve their stability in pharmaceutical formulations. The presence of world-class structural biology alongside classical phage biology and industrial production is precisely the kind of interdisciplinary integration the review identifies as a national strength.

Looking forward, the authors identify several priorities that will determine whether Czech phage therapy can move from promising practice to sustainable standard of care. Sustainable access to standardized phage preparations is paramount: phage therapy is inherently individualized, because phages must be matched to the specific bacterial strain infecting each patient, and bacteria can evolve resistance to individual phages, so therapeutic preparations typically consist of carefully designed cocktails of multiple viruses. Maintaining libraries of well-characterized phages, updating them in response to evolving bacterial populations, and producing them reproducibly under GMP conditions is logistically and financially demanding in ways that conventional small-molecule antibiotics are not. The review argues that this challenge must be addressed within the rapidly evolving European regulatory framework, which is only now beginning to define how individualized biological therapies should be assessed, authorized, and reimbursed.

The broader significance of the Czech experience extends across the continent. As antimicrobial resistance is projected to cause millions of deaths annually in the coming decades, European health systems are actively searching for non-traditional antibacterial therapies, including enzybiotics, phage-derived enzymes that degrade bacterial cell walls, alongside whole-phage treatments. The review’s conclusion is that the Czech Republic has established the substantial expertise and infrastructure needed to serve as an important European contributor to this effort, offering a working model of how a long national tradition, when combined with modern genomics, structural biology, regulatory engagement, and industrial capability, can be transformed into a coherent pathway for integrating phage-based interventions into twenty-first-century healthcare.

Subject of Research: Phage therapy research, clinical practice, and development in the Czech Republic as a contribution to phage therapy in Europe

Article Title: Past and present phage therapy research and practice in the Czech Republic – contribution to phage therapy in Europe

Article References: Pantůček, R., Doškař, J., Boštík, J., Kocourková, D., Petrzik, K., Koptíková, J., Benešík, M., Plevka, P., Füzik, T., Mašlaňová, I., Botka, T., Nepeřený, J., Zeller, D., Kuntová, L., Snopková, K., Hrala, M., & Moša, M. (2026). Past and present phage therapy research and practice in the Czech Republic – contribution to phage therapy in Europe. Virology Journal. https://doi.org/10.1186/s12985-026-03296-x

Image Credits: AI Generated

DOI: 10.1186/s12985-026-03296-x

Keywords: phage therapy, bacteriophages, antimicrobial resistance, Czech Republic, Staphylococcal infections, Stafal, GMP manufacturing, clinical trials, enzybiotics, biocontrol, osteomyelitis, phage-antibiotic synergy